HPNswingtrades

Happy 2015!!!

Hoping it’s another profitable year of trading. My resolution is to share even more ideas to help people benefit and profit so that they can work towards financial freedom!!!

A stock to look at right now is $LOCK

LifeLock, Inc. (NYSE:LOCK) is a leading provider of proactive identity theft protection services for consumers and fraud and risk solutions for enterprises. LifeLock’s threat detection, proactive identity alerts, and comprehensive remediation services help provide some peace of mind for consumers amid the growing threat of identity theft. The LifeLock mobile app helps consumers manage their identity and payment cards on the go and enables LifeLock members to receive alerts and services on their digital devices. Leveraging unique data, science and patented technology from ID Analytics, Inc., a wholly-owned subsidiary, LifeLock offers identity theft protection that goes significantly beyond credit monitoring. As part of its commitment to help fight identity theft, LifeLock works to train law enforcement and partners with a variety of non-profit organizations to help consumers establish positive habits to combat this threat.

In recent trading $LOCK had a false breakout and then plummeted to around $15 per share. It is a steal at this price.

Looking at these pivot points shows that it has much more room to run,

Support & Resistance More 2nd Resistance Point 20.14 1st Resistance Point 18.01 Last Price 15.22 1st Support Level 14.56 2nd Support Level 13.24

As a dietary restriction and for my doctor’s sake I’m trying to keep my caloric intake in line with the S&P 500… So, I’m trying not to consume more than 2072 calories.. Ha! I will probably have more than that on beer alone! I have many reasons to be thankful this year and I am spreading some of that cheer with two great stock ideas.

$RXII

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. They are well positioned to compete successfully in the RNAi-based therapeutics market with an experienced management team, an accomplished Scientific Advisory Board and a strong, broad intellectual proprietary position in RNAi chemistry and delivery.

It is a great short term or long term stock to watch. Look for it to break its first resistance point of $2.39.

$PSDV

pSivida develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. They have developed three of the four products approved in either the U.S. or the EU for sustained release delivery of drug to treat chronic back-of-the-eye diseases utilizing multiple generations of our Durasert™ technology system.

Their lead development product, ILUVIEN^® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology.The US Food and Drug Administration (FDA) approved ILUVIEN for the treatment of diabetic macular edema (DME) for patients treated with a course of corticosteroids and did not have a significant rise in intraocular pressure (IOP).

Look for it to break first resistance point of $4.83.

Trade smart!

Finding beaten down small caps and buying at the right time can lead to huge gains. Here are some small caps that we are looking at…

$ISNS

Headquartered in St. Paul, Minnesota, USA, Image Sensing Systems (ISS) was founded in 1984 to develop products for advanced traffic management systems, traffic data collection applications and related markets. ISS is a publicly traded company. (NASDAQ: ISNS). With more than 135,000 instances sold in over 60 countries worldwide, their depth of experience coupled with breadth of product portfolio uniquely positions them to provide powerful hybrid technology solutions and to exploit the convergence of the traffic, security and environmental management markets and flexible data management applications.

They have had some tough going the past three years, but they have their financials back on track and have a renewed product line up that offers big upside.

$ZAZA

ZaZa Energy Corporation is both a conventional and unconventional exploration and production company with a world-class portfolio consisting of resource assets in Texas, U.S.A. ZaZa’s singular focus is the continuous, safe, and efficient development of its diverse and expanding oil and gas resource portfolio. ZaZa is committed to generating superior shareholder returns by leveraging its industry leading technical expertise to continuously streamline its operations, maximize production and reduce operating costs.

Why are we looking at them? They had god earnings in November…

ZaZa Energy reported earnings of 83 cents a share for the third quarter, up from a loss of $2.01 a share in the third quarter of 2013. Revenue increased 144% year over year to $2.7 million for the quarter, up from $1.1 million in the year-ago quarter.

The company said total operating expenses fell about 60% in the third quarter to $6.3 million from $15.2 million in the third quarter of 2013. General and administrative expenses fell about 30% in the quarter.

$PHMD

PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!™ brand, for various indications including hair removal, acne treatment and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas.

PHMD had a big day today and we expect that it has more room to move.

$LRAD

The Long Range Acoustic Device (LRAD) is a high-intensity directional acoustic hailer designed for long-range communication and issuing powerful warning tones. Layered defense force protection systems must be easily accessible and rapidly deployable for any operational scenario and allow for near instantaneous escalation across the force protection spectrum.

LRAD is a breakthrough directed acoustic hailing device (AHD) designed to communicate with authority and exceptionally high intelligibility. LRAD systems are easy to use through a simple, familiar, and standardized interface. Manual or autonomous systems are designed for around the clock operation in the harshest military conditions.

LRAD released positive earnings giving a great outlook going forward. Keep an eye on this one!

Enjoy these picks. Do your own research and have fun!

Good evening everyone! I hope tonight finds everyone well and raking in profits from calls we had on $VGGL and $SNSS, which have had impressive days recently. We will be releasing a mid-week watch list tomorrow, but we had one stock that we could not wait to unveil.

Drum roll…..

$ALIM

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.

Alimera Sciences’ primary focus is on ILUVIEN^® (fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection.¹

Yesterday they had some major news that lead us to keep a close eye on this stock.

Yesterday Alimera announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN^® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Also, coverage was initiated by Summer Street Research and they put a “Buy” rating on Alimera with a $12 price target. They said, “With the launch of Iluvien in the US ALIM should be able to dramatically grow top and bottom lines through our forecast period and become EPS positive by 2016. We see the 1Q15 Iluvien launch as transformative for ALIM, and we are initiating coverage with a BUY rating and $12 price target.”

With the right volume this could be a mover in the near future!

There are many stocks this week that are walking dead, but fret not my fearless traders, we, at HPN, will lead you on the right path and away for those profit killing zombie stocks!!! Read the following recap from last week and what to watch for this week.

Last week’s recap:

Major U.S. indices moved higher over the past week, as of mid-day trading on Friday afternoon, led by technology stocks on the NASDAQ. In addition to recovering from a rough couple of weeks, the markets were boosted by a 0.8% increase in the Conference Board’s index of leading indicators last month, driven by ongoing gains in employment that should boost incomes and support economic growth. Investors remain concerned with weaker prospects overseas,

What to watch:

$YELP

Yelp saw a large sell off last week after worse than expected earnings. The stock dropped 18% on Thursday. Many analysyts still have a price target on $YELP in the $75-$85 range. We are bullish and $YELP and expect a quick recovery. This is a great stock to but at a huge discount. Investors need to keep in mind that the company originally guided to Q3 revenue of only $98 million to $99 million, but the actual numbers came in significantly higher at $102.5 million. A similar beat in Q4 would bring the actual revenue numbers closer to or even above analyst estimates at $111 million. Even more interesting is that the company guided up the full-year EBITDA forecast from an average of $68 million to a new level of $70 million. Investors should use any sell-off to get into the leading online consumer review site.

$TWTR

Twitter kicks off the week for social media earnings on Monday. After struggling for awhile to meet analyst expectations on monthly active user (MAU) growth, Twitter finally put up a satisfactory quarter this summer. With 271 million MAUs at its back Twitter has been focusing on product improvements to increase the amount of time users spend on its platform, increasing the value of its advertisements. Most notably this quarter Twitter launched Audio Cards, a feature which enables music and podcasts to be played directly on Twitter via Soundcloud. Twitter has a great track record of beating the Street’s EPS consensus and the Estimize consensus believes that pattern will hold on Monday. A great earnings play, but tread with caution playing earnigs is dangerous… but highly profitable.

$CYBR

Shares of Cyberark Software Ltd have experienced volatility in last monday’s trade as the quiet period for shares as expired.

Many top analysts are bullish on this security such as:

• Barclays: Equal-weight rating; $32 price target. Saket Kalia wrote, “Cyberark is a leader in the privileged account security space, with a thorough, well-integrated, and enterprise-ready solution.”
• Oppenheimer: Outperform rating $38 price target. Shaul Eyal stated, “We see CYBR as a solid acquisition candidate in a rapidly consolidating security market, as the leading networking and software companies, flushed with cash, are seeking to expand their product portfolio and increase their product footprint within their vast install bases.”
• Nomura: Buy rating; $36 price target. Nomura analysts find, “CyberArk is positioned to benefit from this increased awareness of the threat and growing evidence that perimeter defenses are not adequate. We believe CyberArk has the ability to capture increased share as it continues to broaden its product line and expand it sales distribution capacity.”
• William Blair: Outperform rating.
• JP Morgan: Neutral rating; $33 price target.

These are the stocks we are focusing on this week. Stay tuned for more stocks to watch soon…

And stay away from the zombies, unless it’s on Walking Dead(love that show)!!!

Let’s face it we all want to make a quick buck. Even value investors get allured by the possibility of a news driven momentum event. Today was a classic example that the market does what it wants and that we cannot expect that a past momentum event will transpire in the same way.

This is evident with the news last night of an Ebola case in New York City. Stocktwits, and other investor websites lit up with traders proclaiming the profits that could be made by Ebola related stocks the following day. So far we haven’t seen the overwhelming breakout that was seen weeks ago.  We, at HPN, documented the Ebola related security opportunity, weeks ago on October 6th. That was a couple of days before the amazing returns came in for securities such as $TKMR, $SRPT, $LAKE, $APT and so on…See this article https://hpnswingtrades.wordpress.com/2014/10/06/ebola-swing-trades/.

Last night when news came in of an Ebola patient in New York City traders were abuzz and many wrote sentiments of waking early on Friday morning to buy securities that they thought would sky rocket during Fridays trading. I mean they did it two weeks ago, so of course they will run again, right???

Well… No they haven’t, and this is a great opportunity to look at ourselves and focus on our own market psychology.

There is plenty of data about chasing trends and the money that can be lost doing so.

We, at HPN, want t make a quick buck too. We are quite honest about this, but we also know the value of reacting to the market. As swing traders we must use all analysis we have at the present moment and react to what’s happening in the market in the moment.

Just beause some news driven momentum broke out weeks ago does not mean that it will happen again in the same way.

Lightning rarely, if ever, strikes twice in the same place.

So, use your analysis, not emotions to make smart trades!